<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00417391</url>
  </required_header>
  <id_info>
    <org_study_id>1101-01</org_study_id>
    <nct_id>NCT00417391</nct_id>
  </id_info>
  <brief_title>Phase II Study of RR110 in Patients With Active Crohn's Disease</brief_title>
  <official_title>Phase II Study of RR110 in Patients With Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R&amp;R Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>R&amp;R Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics profile of
      1 and 4 mg/kg/day RR110 administrated orally for 8 weeks in patients with active Crohn's
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Crohn's disease active index (CDAI) score</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical response as defined by CDAI decrease &gt; 70 or 100 from baseline</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical remission as defined by CDAI &lt; 150</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP, SAA, and fibrinogen levels, and IBDQ and CDEIS scores</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>1 mg RR110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg RR110</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg RR110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg RR110</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RR110 (Tamibarotene)</intervention_name>
    <description>1 mg RR110</description>
    <arm_group_label>1 mg RR110</arm_group_label>
    <other_name>Tamibarotene</other_name>
    <other_name>Am80</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RR110 (Tamibarotene)</intervention_name>
    <description>4 mg RR110</description>
    <arm_group_label>4 mg RR110</arm_group_label>
    <other_name>Tamibarotene</other_name>
    <other_name>Am80</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CDAI score ranging from 220 to 450

          -  Patients with CRP &gt; 1 mg/dL

          -  Patients who can be hospitalized at least 2 weeks after first administration

        Exclusion Criteria:

          -  Patients who have previously used anti-TNF antibody, cyclosporine, methotrexate or
             tacrolimus within 12 weeks of screening

          -  Patients who have had surgical bowel resections within 4 weeks of screening

          -  Patients who have previously used total parental nutrition or more than 900 kcal/day
             of enteral nutrition within 4 weeks of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshifumi Hibi, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Keio University</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakura</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nakagami</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2006</study_first_submitted>
  <study_first_submitted_qc>December 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2007</study_first_posted>
  <last_update_submitted>May 25, 2008</last_update_submitted>
  <last_update_submitted_qc>May 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Miwako Ishido/Manager</name_title>
    <organization>R&amp;R Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

